Durova Tablet 10mg (Leflunomide)

Adult dose

Administer 100 mg once daily for 3 days as the loading dose. For patients with rheumatoid arthritis, administer 20 mg once daily as the maintenance dose. Some patients who received 25 mg daily experienced adverse reactions such as hair loss, weight loss, and increased liver enzyme levels. Therefore, the maintenance dose should not exceed 20 mg daily. If the patient's clinical tolerability is poor, the maintenance dose may be reduced to 10 mg daily. For patients with psoriatic arthritis, administer 20 mg daily as the maintenance dose.

This drug contains active metabolites that remain in the body for a long time, which may cause side effects to appear or persist even after discontinuation. If serious side effects occur or if rapid elimination of the drug from the body is necessary, special drugs (cholestyramine or activated charcoal) should be administered to quickly eliminate this drug. Patients with impaired liver function or a history of liver disease should undergo liver function tests before using this drug and monitor their liver condition regularly during treatment. If liver enzyme levels rise, the dosage may need to be reduced or the medication discontinued, as serious liver damage may occur. The risk of hepatotoxicity may increase when used concomitantly with certain other medications (e.g., methotrexate), so frequent liver function tests are necessary. Patients with pulmonary issues or a history of lung disease should be evaluated by a physician before starting this drug and pay attention to pulmonary symptoms during treatment. As it may suppress immune function, it is not recommended for patients with severe infections or immunodeficiency. Serious skin reactions may occur, so if symptoms such as rash or skin ulcers appear, discontinue use immediately and consult a physician. This drug should not be administered to pregnant women or women of childbearing potential, and if pregnancy is confirmed during treatment, the physician should be notified immediately. Patients with genetic lactose metabolism disorders should not take this drug. No special dosage adjustment is needed for elderly patients over 65 years old, but it is not recommended for use in children under 18 years old. Overdosage may cause diarrhea, abdominal pain, hematological abnormalities, etc., in which case the drug can also be eliminated by administering cholestyramine or activated charcoal. This drug may interact with other medications, so if other drugs are being taken, it is essential to inform the physician or pharmacist. Regular blood tests and liver function tests should be performed during treatment, and medical consultation should be sought immediately if any abnormal symptoms occur. Moreover, as this drug has immunosuppressive effects, care should be taken to prevent infections, and vaccination should be discussed with a physician as necessary. It is advisable to store this drug away from direct sunlight and at a temperature below 25 degrees Celsius.

• Diarrhea
• increased liver enzyme levels (ALT, AST)
• hair loss
• rash
• weakness
• flu-like syndrome
• upper respiratory infection
• injury
• pain
• abdominal pain

This drug is sensitive to light and should be stored in a container that does not allow light to enter. It should also be kept in a sealed container to prevent air from entering, and maintaining a storage temperature below 25 degrees Celsius is essential.

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle